<DOC>
	<DOCNO>NCT00355719</DOCNO>
	<brief_summary>The purpose study evaluate influence nevirapine exposure atazanavir boost ritonavir , steady state equilibrium , HIV-infected adult patient .</brief_summary>
	<brief_title>Study Evaluate Influence Nevirapine Atazanavir Steady State Equilibrium HIV Patients</brief_title>
	<detailed_description>In recent year , new treatment strategy appear aim reduce risk treatment-derived toxicity without compromise efficacy . Of recent antiretroviral drug , atazanavir protease inhibitor ( PI ) whose pharmacokinetic profile allow give single daily take scant impact lipid metabolism . This second characteristic make atazanavir good alternative patient high vascular risk . However , one drawback may present clinically relevant interaction drug . Another antiretroviral agent scant impact lipid metabolism nevirapine . Different study describe improvement lipid profile , well less atherogenic tendency patient treat nevirapine . Moreover , combination nevirapine PI drug context nucleoside-sparing strategy may permit suitable control viral replication , improvement mitochondrial toxicity derive treatment NTRI , may possibly result minor incidence clinical improvement lipodystrophy . The combination atazanavir nevirapine may major interest HIV-infected patient cardiovascular event ( secondary prevention ) high risk one ( primary prevention ) . Similarly , combination drug may promise nucleoside-sparing strategy . However , accord preliminary data , joint administration nevirapine atazanavir may lead reduction atazanavir plasma concentration . Thus , evaluate clinical utility combination drug , pharmacokinetic study evaluate existence significant pharmacokinetic interaction necessary</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Age &gt; =18 year . Patients infected HIV1 ( least one document positive WesternBlot ) . Stable antiretroviral treatment atazanavir boost ritonavir ( 300/100 mg QD ) least 14 day . Absence acute infection and/or tumour three month prior inclusion . Subject able follow treatment period . Transaminase value ( AST/ALT ) 5 time upper limit interval normality . In woman , negative pregnancy test fertile age ( define least one year menopause undergoing surgical sterilisation technique ) , undertake use barrier contraceptive method study . Signature informed consent . Undetectable viral load . Failure comply inclusion criterion . Record allergic hypersensitivity intolerance investigational medication . Any clinical historic observation might interfere pharmacokinetics medication , gastrointestinal disease surgery ( except herniotomy appendectomy ) , alteration composition plasma protein , indication hepatic renal dysfunction . Patients give tenofovir , omeprazole proton pump inhibitor medication relevant interaction atazanavir within two week prior screen visit . Active consumption alcohol ( &gt; 50 g/day ) illegal drug ( except cannabis ) . Suspicion unsuitable antiretroviral treatment compliance . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Nevirapine</keyword>
	<keyword>Atazanavir</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Interactions</keyword>
</DOC>